ARS Pharma Q1 neffy revenue $7.8M, net loss $33.9M; commercial progress with 5,000+ prescribers

ARS Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.35 revenue$7,973,000

Net product revenue of $7.8M from neffy; total revenue $8.0M; net loss $33.9M ($0.35 per share).
Cash, equivalents and investments $275.7M; company says runway adequate for over three years.
More than 5,000 HCPs prescribed neffy; co-promotion with ALK expands reach to ~20,000 HCPs including pediatricians.
57% commercial coverage secured; neffy 1mg now available for children 4+ weighing 15-30 kg.
Regulatory decisions expected mid-2025 in UK, year-end in Canada; German launch mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.